T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Fortinet
FTNT
|
+$2.03B |
| 2 |
Rockwell Automation
ROK
|
+$1.44B |
| 3 |
Autodesk
ADSK
|
+$1.15B |
| 4 |
Citigroup
C
|
+$975M |
| 5 |
ConocoPhillips
COP
|
+$967M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$2.59B |
| 2 |
GE Aerospace
GE
|
+$1.78B |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$1.38B |
| 4 |
Meta Platforms (Facebook)
META
|
+$1.08B |
| 5 |
Philip Morris
PM
|
+$1.06B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 32.21% |
| 2 | Healthcare | 15.42% |
| 3 | Financials | 10.99% |
| 4 | Consumer Discretionary | 10.39% |
| 5 | Communication Services | 8.82% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
526
Curtiss-Wright
CW
$25.4B
| $112M | 0.01% |
439,500
-738
| -0.2% | -$172K |
|
527
OR Royalties Inc
OR
$6.15B
| $110M | 0.01% |
+6,688,471
| New | +$98.8M |
|
528
Parker-Hannifin
PH
$134B
| $109M | 0.01% |
196,960
+15,079
| +8% | +$7.66M |
|
529
Arthur J. Gallagher & Co
AJG
$65B
| $109M | 0.01% |
435,575
-111,064
| -20% | -$26.7M |
|
530
Moderna
MRNA
$25.4B
| $109M | 0.01% |
1,019,197
-88,298
| -8% | -$8.9M |
|
531
ZTO Express
ZTO
$17.4B
| $108M | 0.01% |
5,180,444
+1,968,971
| +61% | +$37.7M |
|
532
The Ensign Group
ENSG
$10.6B
| $108M | 0.01% |
870,018
-1,428
| -0.2% | -$171K |
|
533
Verisk Analytics
VRSK
$24.2B
| $108M | 0.01% |
456,674
-10,955
| -2% | -$2.63M |
|
534
MoonLake Immunotherapeutics
MLTX
$1.4B
| $107M | 0.01% |
2,135,883
-178,129
| -8% | -$9.66M |
|
535
Baidu
BIDU
$35.5B
| $107M | 0.01% |
1,017,341
+84,776
| +9% | +$9.03M |
|
|
PR
536
Permian Resources
PR
$17.7B
| $107M | 0.01% |
6,054,560
+5,012,287
| +481% | +$73.5M |
|
537
Kraft Heinz
KHC
$30.1B
| $107M | 0.01% |
2,896,155
-12,570,383
| -81% | -$457M |
|
538
Manhattan Associates
MANH
$11.7B
| $107M | 0.01% |
426,729
+29,063
| +7% | +$6.92M |
|
539
Prothena Corp
PRTA
$466M
| $104M | 0.01% |
4,201,771
-35,580
| -0.8% | -$1.06M |
|
540
NiSource
NI
$20.2B
| $104M | 0.01% |
3,754,122
-218,619
| -6% | -$5.75M |
|
541
NetEase
NTES
$78.5B
| $104M | 0.01% |
+1,001,816
| New | +$102M |
|
542
Medpace
MEDP
$16.2B
| $104M | 0.01% |
256,100
+3,222
| +1% | +$1.13M |
|
543
New Oriental
EDU
$8.33B
| $103M | 0.01% |
+1,190,859
| New | +$101M |
|
544
Vera Therapeutics
VERA
$2.08B
| $103M | 0.01% |
+2,393,029
| New | +$85.3M |
|
545
Murphy USA
MUSA
$10.4B
| $103M | 0.01% |
245,220
+1,519
| +0.6% | +$594K |
|
|
AKRO
546
DELISTED
Akero Therapeutics
AKRO
| $103M | 0.01% |
4,060,479
+384,555
| +10% | +$9.24M |
|
547
Ciena
CIEN
$62.7B
| $102M | 0.01% |
2,062,394
+1,961,513
| +1,944% | +$103M |
|
548
Builders FirstSource
BLDR
$7.91B
| $101M | 0.01% |
484,907
-27,959
| -5% | -$5.17M |
|
549
Bruker
BRKR
$8.83B
| $99.7M | 0.01% |
1,061,624
-311,924
| -23% | -$25.1M |
|
550
Wynn Resorts
WYNN
$10.5B
| $99.4M | 0.01% |
972,291
-20,883
| -2% | -$2.07M |
|
Similar funds
T. Rowe Price Associates's Q1 2024 Portfolio in Review
As of Q1 2024, T. Rowe Price Associates held 3,021 positions worth $816B, up 9.6% from $744B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q1 2024 filing shows 108 new, 1,941 increased, 738 reduced and 64 closed positions. Its largest new stake was GE Vernova: 2,687,194 shares worth $367M. The largest sale was NVIDIA, an estimated $2.59B.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 31% a quarter earlier, followed by Healthcare and Financials.
- T. Rowe Price Associates's largest Q1 2024 buy was GE Vernova: 2,687,194 shares worth $367M.
- T. Rowe Price Associates added most to Fortinet in Q1 2024, an estimated $2.03B increase.
- T. Rowe Price Associates's biggest Q1 2024 reduction was NVIDIA, cutting an estimated $2.59B.
- T. Rowe Price Associates fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $621M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $816B portfolio in Q1 2024.
- T. Rowe Price Associates opened 108 new positions and closed 64 in Q1 2024.
- T. Rowe Price Associates's portfolio value rose 9.6% quarter-over-quarter to $816B.
Based on T. Rowe Price Associates's 13F filing for Q1 2024, filed 15 May 2024.